ReviewHematology/oncology clinics of North America2022
Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms.
Review in Hematology/oncology clinics of North America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05170594 (A Prospective Study of Bevacizumab Combined With Fluzoparib, Bevacizumab Combined With Chemotherapy or Fluzoparib Monotherapy in the Treatment of Platinum-resistant Recurrent Ovarian Cancer), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Study of Bevacizumab Combined With Fluzoparib, Bevacizumab Combined With Chemotherapy or Fluzoparib Monotherapy in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Cancer treatment-related cognitive impairment.Neuro-oncology advances · 2026Review
- Predicting IDH Mutation in Glioma Patients Using Deep Learning Algorithms with Conformal Prediction.Journal of imaging informatics in medicine · 2026Article
- Cell-Free DNA (cfDNA), Its Applications in Cancer Diagnosis and Monitoring, and Its Potential Role in Regulating Cancer Metabolism.Advances in experimental medicine and biology · 2026Review
- The Association between p53 Expression and Histopathology Grade of Astrocytoma.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Assessing the predictability of isocitrate dehydrogenase mutational status in glioma patients using imaging features.Surgical neurology international · 2025Article
- Overcoming immunotherapy resistance in glioblastoma: challenges and emerging strategies.Frontiers in pharmacology · 2025Review
- Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth.Molecular cancer research : MCR · 2024Article
- Frailty in patients with IDH-mutant gliomas: experience from a high-volume tumor center.Journal of neuro-oncology · 2024Article
- (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.Cancer discovery · 2023Article
- Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2023Article
- Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas.International journal of cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
Mutations in isocitrate dehydrogenase (IDH) 1 or IDH2 occur in most of the adult low-grade gliomas and, less commonly, in cholangiocarcinoma, chondrosarcoma, acute myeloid leukemia, and other human malignancies. Cancer-associated mutations alter the function of the enzyme, resulting in production of R(-)-2-hydroxyglutarate and broad epigenetic dysregulation. Small molecule IDH inhibitors have received regulatory approval for the treatment of IDH mutant (mIDH) leukemia and are under development for the treatment of mIDH solid tumors. This article provides a current view of mIDH adult astrocytic and oligodendroglial tumors, including their clinical presentation and treatment, and discusses novel approaches and challenges toward improving the treatment of these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.